Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults
Mark A. Brockman, Francis Mwimanzi, Hope R. Lapointe, et al.
The Journal of Infectious Diseases (2021) Vol. 225, Iss. 7, pp. 1129-1140
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 178
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
Zabrina L. Brumme, Francis Mwimanzi, Hope R. Lapointe, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 84
Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
Evropi Amanatidou, Anna Gkiouliava, Eva Pella, et al.
Metabolism Open (2022) Vol. 14, pp. 100180-100180
Open Access | Times Cited: 67
Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong
Lin‐Lei Chen, Syed Muhammad Umer Abdullah, Wan-Mui Chan, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 64
Age-associated alterations in immune function and inflammation
Erin D. Lewis, Dayong Wu, Simin Nikbin Meydani
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2022) Vol. 118, pp. 110576-110576
Open Access | Times Cited: 46
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Andrés Chang, Akil Akhtar, Susanne L. Linderman, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 26, pp. 3020-3031
Open Access | Times Cited: 40
Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose
Francis Mwimanzi, Hope R. Lapointe, Peter K. Cheung, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 6, pp. 983-994
Open Access | Times Cited: 38
Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses
Yang Yang, Fang Li, Lanying Du
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
COVID-19 vaccine immunogenicity in people with HIV
Cecilia T. Costiniuk, Joel Singer, Terry Lee, et al.
AIDS (2022) Vol. 37, Iss. 1, pp. F1-F10
Open Access | Times Cited: 27
Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly
Isabella A. T. M. Ferreira, Colin Y. C. Lee, William S. Foster, et al.
Cell Reports (2023) Vol. 42, Iss. 8, pp. 112991-112991
Open Access | Times Cited: 16
SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series
Chapin S. Korosec, David W. Dick, Iain R. Moyles, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Long-term antibody responses to COVAXIN and COVISHIELD vaccines in rheumatoid arthritis patients and healthy control population – A cross-sectional study
Vijaya Prasanna Parimi, Anand Pyati, Madhavi Eerike
Journal of Family Medicine and Primary Care (2025) Vol. 14, Iss. 1, pp. 107-114
Open Access
COVID-19 booster doses reduce sex disparities in antibody responses among nursing home residents
Oladayo A. Oyebanji, Anna Yin, Nicholas Sundheimer, et al.
Aging Clinical and Experimental Research (2025) Vol. 37, Iss. 1
Open Access
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
María Eugenia Toledo-Romaní, Mayra García-Carmenate, Leslyhana Verdecia-Sánchez, et al.
Med (2022) Vol. 3, Iss. 11, pp. 760-773.e5
Open Access | Times Cited: 25
Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection
Katja Schmidt, Ellen G. Harrer, Koray Taşçılar, et al.
Viruses (2022) Vol. 14, Iss. 3, pp. 651-651
Open Access | Times Cited: 23
Process development for an effective COVID-19 vaccine candidate harboring recombinant SARS-CoV-2 delta plus receptor binding domain produced by Pichia pastoris
Sibel Kalyoncu, Semiramis Yılmaz, Ayça Zeybek Kuyucu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults
Devyani Joshi, Lindsay E. Nyhoff, Veronika I. Zarnitsyna, et al.
iScience (2023) Vol. 26, Iss. 10, pp. 107967-107967
Open Access | Times Cited: 12
Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination
Hakjun Hyun, Eliel Nham, Hye Seong, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study
Prasad S. Kulkarni, Abhijit N. Kadam, Sheela Godbole, et al.
The Lancet Regional Health - Southeast Asia (2023) Vol. 10, pp. 100139-100139
Open Access | Times Cited: 10
Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review
Nina Kreuzberger, Caroline Hirsch, Marike Andreas, et al.
Cochrane library (2022) Vol. 2022, Iss. 8
Open Access | Times Cited: 17
SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain
Israel López-Muñoz, Ariadna Torrella, Olga Pérez‐Quílez, et al.
Emerging infectious diseases (2022) Vol. 28, Iss. 10, pp. 1999-2008
Open Access | Times Cited: 16
Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2
Quentin Clairon, Mélanie Prague, Delphine Planas, et al.
PLoS Computational Biology (2023) Vol. 19, Iss. 8, pp. e1011282-e1011282
Open Access | Times Cited: 9
Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
Haruka Maeda, Nobuo Saito, Ataru Igarashi, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 11, pp. 1971-1979
Open Access | Times Cited: 14
Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged ≥60 years: Estimates over calendar time and by time since administration during prevalent circulation of different Omicron subvariants, Italy, 2022–2023
Massimo Fabiani, Alberto Mateo‐Urdiales, Chiara Sacco, et al.
Vaccine (2024) Vol. 42, Iss. 23, pp. 126026-126026
Open Access | Times Cited: 2
Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: comparison between inactivated and mRNA vaccine
Ngai Sze Wong, Bonnie C.K. Wong, Jacky Man Chun Chan, et al.
AIDS (2022) Vol. 36, Iss. 9, pp. 1255-1264
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top